NO20090951L - Nytt eukalyptusekstrakt, fremgangsmate for fremstilling og terapeutiske anvendelser derav - Google Patents

Nytt eukalyptusekstrakt, fremgangsmate for fremstilling og terapeutiske anvendelser derav

Info

Publication number
NO20090951L
NO20090951L NO20090951A NO20090951A NO20090951L NO 20090951 L NO20090951 L NO 20090951L NO 20090951 A NO20090951 A NO 20090951A NO 20090951 A NO20090951 A NO 20090951A NO 20090951 L NO20090951 L NO 20090951L
Authority
NO
Norway
Prior art keywords
preparation
new
eucalyptus extract
therapeutic uses
isobutyl
Prior art date
Application number
NO20090951A
Other languages
English (en)
Inventor
Bernard Fabre
Christel Fiorini-Puybaret
Cecile Chauvin
Philippe Joulia
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20090951L publication Critical patent/NO20090951L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det beskrives anvendelse av et eukalyptusekstrakt for fremstilling av et medikament eller et diettsupplement ment for terapi og/eller prevensjon av addiksjoner eller patologier forårsaket av neuromediator gjenopptaksforstyrrelser.Det beskrives videre et nytt, anriket ekstrakt av eukalyptus som karakteriseres ved at den inneholder minst en forbindelse med formel (I) eller en hvilken som helst av dens diastereoisomerer der RI danner en C=CHsubstituent med karbonatomet hvortil den er bundet, en formel (II) substituent og R2 representerer en isobutyl, a-isobutyl eller P-isobutyl substituent.Forbindelsenes fremstilling beskrives.
NO20090951A 2006-08-01 2009-03-02 Nytt eukalyptusekstrakt, fremgangsmate for fremstilling og terapeutiske anvendelser derav NO20090951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0607201A FR2904557B1 (fr) 2006-08-01 2006-08-01 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
PCT/FR2007/001309 WO2008017752A2 (fr) 2006-08-01 2007-07-27 Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques

Publications (1)

Publication Number Publication Date
NO20090951L true NO20090951L (no) 2009-04-24

Family

ID=37708427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090951A NO20090951L (no) 2006-08-01 2009-03-02 Nytt eukalyptusekstrakt, fremgangsmate for fremstilling og terapeutiske anvendelser derav

Country Status (20)

Country Link
US (1) US20090324754A1 (no)
EP (1) EP2049133A2 (no)
JP (1) JP2010500974A (no)
KR (1) KR20090034401A (no)
CN (1) CN101511378A (no)
AR (1) AR062165A1 (no)
AU (1) AU2007283529A1 (no)
BR (1) BRPI0714863A2 (no)
CA (1) CA2659162A1 (no)
FR (1) FR2904557B1 (no)
IL (1) IL196788A0 (no)
MA (1) MA30592B1 (no)
MX (1) MX2009000673A (no)
NO (1) NO20090951L (no)
NZ (1) NZ574429A (no)
RU (1) RU2445112C2 (no)
TN (1) TN2009000018A1 (no)
TW (1) TW200820961A (no)
UA (1) UA99598C2 (no)
WO (1) WO2008017752A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926547B1 (fr) * 2008-01-18 2010-04-23 Pf Medicament 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments.
JP5602346B2 (ja) 2008-06-17 2014-10-08 株式会社ロッテ ユーカリ抽出物の調製方法
GB2465228A (en) * 2008-11-15 2010-05-19 Athena Health Patents Inc Analogues of phloroglucinols from eucalyptus plant varieties and related compounds and their use in treating neurodegenerative disorders
CN102085169B (zh) * 2011-01-30 2012-08-29 广州中涵生物科技有限公司 一种使黑头溶解同步收细毛孔的制剂
PT106278B (pt) * 2012-04-26 2018-01-03 Raiz Inst De Investigação Da Floresta E Papel Método para a obtenção de um extrato rico em ácidos triterpénicos a partir da casca de eucalipto
KR102115037B1 (ko) * 2013-12-04 2020-05-25 코웨이 주식회사 상고머리 야테 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물
US20160317596A1 (en) * 2013-12-18 2016-11-03 Thylabisco Ab Use of Thylakoids to Reduce the Urge for Palatable Food
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
CN109172554A (zh) * 2018-09-06 2019-01-11 淮安安莱生物科技有限公司 大果桉醛c在制备治疗人肝癌的药物方面的应用
KR102212193B1 (ko) 2019-07-15 2021-02-03 박경호 인동등 및 유칼립투스 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329297A1 (fr) * 1975-10-29 1977-05-27 Rougier Yves Inhalateur buccal
JP3365782B2 (ja) * 1990-11-22 2003-01-14 株式会社ロッテ 新規マクロカルパール類及びその製造法
DE4447336C2 (de) * 1994-12-31 1996-12-19 Goebel Hartmut J Dr Med Habil Verwendung eines Gemisches aus Cineol und Menthol
JPH08198765A (ja) * 1995-01-31 1996-08-06 Hayami Kinugawa 鎮痛用医薬組成物
JPH11137232A (ja) * 1997-08-02 1999-05-25 Ever Bright Ind Corp ハーブ製品
JP4809980B2 (ja) * 2000-01-18 2011-11-09 長岡香料株式会社 抗動脈硬化症剤
US20010036488A1 (en) * 2000-01-18 2001-11-01 Syuichi Hayashi Anti-obestic composition
CA2470603A1 (en) * 2001-12-19 2003-07-03 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
JP4979181B2 (ja) * 2003-01-31 2012-07-18 株式会社ヤクルト本社 グリケーション阻害剤及びその利用
JP2005272431A (ja) * 2004-03-24 2005-10-06 Yukio Kitagawa アロマセラピー品

Also Published As

Publication number Publication date
RU2445112C2 (ru) 2012-03-20
BRPI0714863A2 (pt) 2013-05-21
FR2904557A1 (fr) 2008-02-08
US20090324754A1 (en) 2009-12-31
AR062165A1 (es) 2008-10-22
RU2009107166A (ru) 2010-09-10
NZ574429A (en) 2012-01-12
WO2008017752A3 (fr) 2008-04-10
KR20090034401A (ko) 2009-04-07
FR2904557B1 (fr) 2010-04-30
UA99598C2 (ru) 2012-09-10
EP2049133A2 (fr) 2009-04-22
TN2009000018A1 (fr) 2010-08-19
WO2008017752A2 (fr) 2008-02-14
TW200820961A (en) 2008-05-16
CN101511378A (zh) 2009-08-19
MA30592B1 (fr) 2009-07-01
AU2007283529A1 (en) 2008-02-14
JP2010500974A (ja) 2010-01-14
IL196788A0 (en) 2009-11-18
CA2659162A1 (fr) 2008-02-14
MX2009000673A (es) 2009-02-04

Similar Documents

Publication Publication Date Title
NO20090951L (no) Nytt eukalyptusekstrakt, fremgangsmate for fremstilling og terapeutiske anvendelser derav
WO2008033460A3 (en) Treating pain, diabetes, and lipid metabolism disorders
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
WO2009016410A3 (en) Chemical compounds 831
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
MX2011008839A (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de transportador de glucosa dependiente de sodio 1.
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX337396B (es) Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2008132552A3 (en) Omega-3 lipid compounds
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
BR112012022632A2 (pt) Medicamento compreendendo agonista de ep4
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
MX2012001107A (es) Derivado de amida.
WO2007104933A8 (en) Chemical compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application